Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.
Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), Li Weng, Santiago Barrio, Joan Bladé(Hospital Clínic de Barcelona), François Pépin, Immaculada Rapado(Hospital Universitario 12 De Octubre), Bruno Paiva(Navarre Institute of Health Research), Ramón García‐Sánz(Centro de Investigación del Cáncer), Maria Jesus Blachard(Hospital Universitario Ramón y Cajal), Rosa Ayala(Hospital Universitario 12 De Octubre), María Ángeles Montalbán(Hospital Universitario 12 De Octubre), Laura Montejano(Hospital Universitario 12 De Octubre), Rafael Martínez(Hospital Clínico San Carlos), Pedro Sánchez‐Godoy(Hospital Universitario Severo Ochoa), Malek Faham, Jesús F. San Miguel(Clinica Universidad de Navarra)
Cited by 2
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k